Olanzapine Fluoxetine Combination (OFC) + Placebo

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Bipolar Depression

Conditions

Bipolar Depression

Trial Timeline

Apr 1, 2009 โ†’ Feb 1, 2012

About Olanzapine Fluoxetine Combination (OFC) + Placebo

Olanzapine Fluoxetine Combination (OFC) + Placebo is a approved stage product being developed by Eli Lilly for Bipolar Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT00844857. Target conditions include Bipolar Depression.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00844857ApprovedCompleted

Competing Products

20 competing products in Bipolar Depression

See all competitors
ProductCompanyStageHype Score
OlanzapineEli LillyPhase 3
77
Valproate + Lithium + Risperidone + OlanzapineEli LillyPhase 3
77
Olanzapine + PlaceboEli LillyApproved
85
FK949EAstellas PharmaPhase 3
77
FK949EAstellas PharmaPhase 3
77
FK949E + PlaceboAstellas PharmaPhase 2/3
65
Escitalopram + Bupropion XLLupin LimitedPhase 3
77
OlanzapineEli LillyApproved
85
Olanzapine Hydrochloride + Lithium CarbonateEli LillyPhase 3
77
olanzapine + lithium + valproate + carbamazepineEli LillyPhase 3
77
OlanzapineEli LillyApproved
85
OlanzapineEli LillyPhase 3
77
LY2979165 + PlaceboEli LillyPhase 1
33
olanzapine + divalproex sodium + placeboEli LillyApproved
85
olanzapine + risperidoneEli LillyApproved
85
LY2979165 + placeboEli LillyPhase 1
33
Topiramate + PlaceboEli LillyApproved
85
olanzapineEli LillyPhase 3
77
Olanzapine + PlaceboEli LillyPhase 3
77
Brenipatide + PlaceboEli LillyPhase 2
52